Abstract | PURPOSE: METHODS: Eligibility criteria included hormone refractory prostate cancer with a rising PSA at least 6 weeks after peripheral anti- androgen withdrawal, ECOG performance status (PS) 0-1, and no prior chemotherapy. Fenretinide was administered orally at 900 mg m(-2) twice daily for 7 of every 21 days. PSA was measured before each cycle. The primary endpoint was a > or =50% reduction in PSA maintained for at least 3 weeks; secondary endpoints included duration of PSA response, time to treatment failure (TTF: treatment stopped for progression or toxicity) and adverse events (AE). RESULTS: Twenty seven pts were recruited from 7 centres over 27 months. Median age was 74 (range 49-86), median baseline PSA was 129 (range 19-1,000), and 70% had a PS of 0. The median number of cycles received was 2 (range 0-11) and 20 pts completed at least 1 cycle. One pt (4%) achieved a 50% reduction in PSA lasting 39 days and 15 pts (56%) had not progressed within 6 weeks of starting fenretinide. The median TTF was 54 days (IQR 19-73): 22 (81%) failed with tumour progression, 3 (11%) failed with toxicity and 2 (7%) never commenced the drug. Grade 3 rash occurred in 1 patient, all other AE were grade 1 or 2. The most common AE were nausea (40%), hot flushes (36%), constipation (32%) and nyctalopia (32%). CONCLUSION: High-dose fenretinide had limited anti-tumour activity in patients with advanced hormone refractory prostate cancer: further evaluation in this setting is not warranted.
|
Authors | M M Moore, M Stockler, R Lim, T S K Mok, M Millward, M J Boyer |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 66
Issue 5
Pg. 845-50
(Oct 2010)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 20082080
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents
- Fenretinide
- Prostate-Specific Antigen
|
Topics |
- Administration, Oral
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Disease Progression
- Fenretinide
(adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(drug therapy, pathology)
- Treatment Failure
|